According to a new report, published by KBV research, The Global Conjunctivitis Treatment Market size is expected to reach $6.1 billion by 2030, rising at a market growth of 4.7% CAGR during the forecast period.
The Viral Conjunctivitis segment is registering a CAGR of 5% during (2023 - 2030). The prevalence of viral conjunctivitis fuels an increased demand for antiviral medications within the conjunctivitis treatment market. Patients seek effective treatments to alleviate symptoms and reduce the duration of the viral infection. The increasing incidence of viral conjunctivitis drives advancements in diagnostic technologies for accurate viral identification. Rapid diagnostic and molecular diagnostics become crucial in distinguishing viral from other forms of conjunctivitis, guiding appropriate treatment strategies.
The Hospital Pharmacy segment is leading the Global Conjunctivitis Treatment Market; thereby, achieving a market value of $3.3 billion by 2030. Hospital pharmacies are equipped to handle various specialized medications and formulations that may be prescribed for conjunctivitis treatment. This includes not only standard eye drops but also specialized formulations. Patients may require inpatient care in cases of severe conjunctivitis or when the condition is part of a larger health concern. Hospital pharmacies play an important role in providing medications for inpatients, ensuring they receive appropriate treatment as part of a broader healthcare intervention.
The Antiviral segment would showcase a CAGR of 5% during (2023 - 2030). Antiviral drugs primarily treat viral conjunctivitis by targeting the underlying viral infection. By inhibiting the virus's replication, these medications diminish the intensity and extent of symptoms. In cases where conjunctivitis is caused by herpes simplex virus, antiviral drugs such as acyclovir, valacyclovir, or ganciclovir may be prescribed. These medications are effective against the herpes simplex virus and help manage ocular symptoms.
Full Report: https://www.kbvresearch.com/conjunctivitis-treatment-market/
The North America region dominated the Global Conjunctivitis Treatment Market, by region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2.2 billion by 2030. The Europe region is experiencing a CAGR of 4.4% during (2023 - 2030). Additionally, The Asia Pacific region would a CAGR of 5.5% during (2023 - 2030).
By Disease Type
By Drug Class
By Distribution Channel
Unique Offerings 
